Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Prices $10.4M Private Placement

NEW YORK (GenomeWeb) – Molecular diagnostics firm OpGen has priced a private placement in which it hopes to raise $10.4 million.

The Gaithersburg, Maryland-based firm will issue 9,053,556 units at a price of $1.14375 each, consisting of one share of common stock and a warrant to purchase three quarters of one share. The five-year warrants will be exercisable 90 days after the placement closes, with an exercise price of $1.3125 per share.

OpGen said it plans to use the proceeds to support sales and marketing, R&D for its diagnostic and bioinformatics products and services, as well as general corporate purposes.

OpGen ended 2015 with $7.8 million in cash and cash equivalents following a $17.1 million initial public offering in May 2015. The firm is scheduled to release its first quarter 2016 results after the market closes today.

The firm's Acuitas MDRO test and Acuitas Lighthouse MDRO management software has been supporting an effort by the city of Washington, DC to gauge the prevalence of multidrug-resistant organisms in healthcare facilities.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.